NCT01819389

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Hospital Universitario Dr. Jose E. Gonzalez · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if low-dose imatinib and nilotinib combination, will improve treatment results in CML patients with failure, suboptimal response or intolerance to imatinib therapy. The hypothesis is that with low-dose imatinib and nilotinib combination, major molecular response will be achieved in patients not previously obtained with imatinib monotherapy.

Conditions

• Leukemia, Myeloid, Chronic, BCR-ABL Positive

Interventions

Type	Name	Description
DRUG	Imatinib and Nilotinib

Timeline

• Start date: 2012-10-01
• Primary completion: 2013-07-01
• Completion: 2013-08-01
• First posted: 2013-03-27
• Last updated: 2014-01-07

Locations

1 site across 1 country: Mexico